Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 25

1.

Physiologically Based Pharmacokinetic Models for Prediction of Complex CYP2C8 and OATP1B1 (SLCO1B1) Drug-Drug-Gene Interactions: A Modeling Network of Gemfibrozil, Repaglinide, Pioglitazone, Rifampicin, Clarithromycin and Itraconazole.

Türk D, Hanke N, Wolf S, Frechen S, Eissing T, Wendl T, Schwab M, Lehr T.

Clin Pharmacokinet. 2019 Dec;58(12):1595-1607. doi: 10.1007/s40262-019-00777-x.

PMID:
31129789
2.

A Comprehensive Whole-Body Physiologically Based Pharmacokinetic Model of Dabigatran Etexilate, Dabigatran and Dabigatran Glucuronide in Healthy Adults and Renally Impaired Patients.

Moj D, Maas H, Schaeftlein A, Hanke N, Gómez-Mantilla JD, Lehr T.

Clin Pharmacokinet. 2019 Dec;58(12):1577-1593. doi: 10.1007/s40262-019-00776-y.

PMID:
31104266
3.

Translational PBPK Modeling of the Protein Therapeutic and CD95L Inhibitor Asunercept to Develop Dose Recommendations for Its First Use in Pediatric Glioblastoma Patients.

Hanke N, Kunz C, Thiemann M, Fricke H, Lehr T.

Pharmaceutics. 2019 Apr 1;11(4). pii: E152. doi: 10.3390/pharmaceutics11040152.

4.

Physiologically-Based Pharmacokinetic Models for CYP1A2 Drug-Drug Interaction Prediction: A Modeling Network of Fluvoxamine, Theophylline, Caffeine, Rifampicin, and Midazolam.

Britz H, Hanke N, Volz AK, Spigset O, Schwab M, Eissing T, Wendl T, Frechen S, Lehr T.

CPT Pharmacometrics Syst Pharmacol. 2019 May;8(5):296-307. doi: 10.1002/psp4.12397. Epub 2019 Mar 13.

5.

PBPK Models for CYP3A4 and P-gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin.

Hanke N, Frechen S, Moj D, Britz H, Eissing T, Wendl T, Lehr T.

CPT Pharmacometrics Syst Pharmacol. 2018 Oct;7(10):647-659. doi: 10.1002/psp4.12343. Epub 2018 Sep 7.

6.

Population nutrikinetics of green tea extract.

Scholl C, Lepper A, Lehr T, Hanke N, Schneider KL, Brockmöller J, Seufferlein T, Stingl JC.

PLoS One. 2018 Feb 21;13(2):e0193074. doi: 10.1371/journal.pone.0193074. eCollection 2018.

7.

A physiologically based pharmacokinetic (PBPK) parent-metabolite model of the chemotherapeutic zoptarelin doxorubicin-integration of in vitro results, Phase I and Phase II data and model application for drug-drug interaction potential analysis.

Hanke N, Teifel M, Moj D, Wojtyniak JG, Britz H, Aicher B, Sindermann H, Ammer N, Lehr T.

Cancer Chemother Pharmacol. 2018 Feb;81(2):291-304. doi: 10.1007/s00280-017-3495-2. Epub 2017 Dec 4.

PMID:
29204687
8.

Clarithromycin, Midazolam, and Digoxin: Application of PBPK Modeling to Gain New Insights into Drug-Drug Interactions and Co-medication Regimens.

Moj D, Hanke N, Britz H, Frechen S, Kanacher T, Wendl T, Haefeli WE, Lehr T.

AAPS J. 2017 Jan;19(1):298-312. doi: 10.1208/s12248-016-0009-9. Epub 2016 Nov 7.

PMID:
27822600
9.

Primary skeletal muscle cells cultured on gelatin bead microcarriers develop structural and biochemical features characteristic of adult skeletal muscle.

Kubis HP, Scheibe RJ, Decker B, Hufendiek K, Hanke N, Gros G, Meissner JD.

Cell Biol Int. 2016 Apr;40(4):364-74. doi: 10.1002/cbin.10565. Epub 2016 Jan 20.

PMID:
26610066
10.

Inhibition of aldosterone synthase (CYP11B2) by torasemide prevents atrial fibrosis and atrial fibrillation in mice.

Adam O, Zimmer C, Hanke N, Hartmann RW, Klemmer B, Böhm M, Laufs U.

J Mol Cell Cardiol. 2015 Aug;85:140-50. doi: 10.1016/j.yjmcc.2015.05.019. Epub 2015 Jun 3.

PMID:
26047574
11.

Identification of 4-(4-nitro-2-phenethoxyphenyl)pyridine as a promising new lead for discovering inhibitors of both human and rat 11β-Hydroxylase.

Hu Q, Kunde J, Hanke N, Hartmann RW.

Eur J Med Chem. 2015;96:139-50. doi: 10.1016/j.ejmech.2015.04.013. Epub 2015 Apr 8.

PMID:
25874338
12.

Discovery of new 7-substituted-4-imidazolylmethyl coumarins and 4'-substituted-2-imidazolyl acetophenones open analogues as potent and selective inhibitors of steroid-11β-hydroxylase.

Stefanachi A, Hanke N, Pisani L, Leonetti F, Nicolotti O, Catto M, Cellamare S, Hartmann RW, Carotti A.

Eur J Med Chem. 2015 Jan 7;89:106-14. doi: 10.1016/j.ejmech.2014.10.021. Epub 2014 Oct 13.

PMID:
25462231
13.

Metabolic stability optimization and metabolite identification of 2,5-thiophene amide 17β-hydroxysteroid dehydrogenase type 2 inhibitors.

Gargano EM, Perspicace E, Hanke N, Carotti A, Marchais-Oberwinkler S, Hartmann RW.

Eur J Med Chem. 2014 Nov 24;87:203-19. doi: 10.1016/j.ejmech.2014.09.061. Epub 2014 Sep 20.

PMID:
25259513
14.

Potent 11β-hydroxylase inhibitors with inverse metabolic stability in human plasma and hepatic S9 fractions to promote wound healing.

Zhu W, Hu Q, Hanke N, van Koppen CJ, Hartmann RW.

J Med Chem. 2014 Sep 25;57(18):7811-7. doi: 10.1021/jm501004t. Epub 2014 Sep 8.

PMID:
25176013
15.

Novel, potent and selective 17β-hydroxysteroid dehydrogenase type 2 inhibitors as potential therapeutics for osteoporosis with dual human and mouse activities.

Perspicace E, Cozzoli L, Gargano EM, Hanke N, Carotti A, Hartmann RW, Marchais-Oberwinkler S.

Eur J Med Chem. 2014 Aug 18;83:317-37. doi: 10.1016/j.ejmech.2014.06.036. Epub 2014 Jun 17.

PMID:
24974351
16.

Inhibition of 17β-HSD1: SAR of bicyclic substituted hydroxyphenylmethanones and discovery of new potent inhibitors with thioether linker.

Abdelsamie AS, Bey E, Hanke N, Empting M, Hartmann RW, Frotscher M.

Eur J Med Chem. 2014 Jul 23;82:394-406. doi: 10.1016/j.ejmech.2014.05.074. Epub 2014 Jun 3.

PMID:
24929290
17.

Design, synthesis, and structure-activity relationships of azolylmethylpyrroloquinolines as nonsteroidal aromatase inhibitors.

Ferlin MG, Carta D, Bortolozzi R, Ghodsi R, Chimento A, Pezzi V, Moro S, Hanke N, Hartmann RW, Basso G, Viola G.

J Med Chem. 2013 Oct 10;56(19):7536-51. doi: 10.1021/jm400377z. Epub 2013 Sep 27.

PMID:
24025069
18.

Cushing's syndrome: development of highly potent and selective CYP11B1 inhibitors of the (pyridylmethyl)pyridine type.

Emmerich J, Hu Q, Hanke N, Hartmann RW.

J Med Chem. 2013 Aug 8;56(15):6022-32. doi: 10.1021/jm400240r. Epub 2013 Jul 19.

PMID:
23869452
19.

Mutations in Arg143 and Lys192 of the Human Mast Cell Chymase Markedly Affect the Activity of Five Potent Human Chymase Inhibitors.

Ahooghalandari P, Hanke N, Thorpe M, Witte A, Messinger J, Hellman L.

PLoS One. 2013 Jun 19;8(6):e65988. doi: 10.1371/journal.pone.0065988. Print 2013.

20.

Gene regulation mediating fiber-type transformation in skeletal muscle cells is partly glucose- and ChREBP-dependent.

Hanke N, Scheibe RJ, Manukjan G, Ewers D, Umeda PK, Chang KC, Kubis HP, Gros G, Meissner JD.

Biochim Biophys Acta. 2011 Mar;1813(3):377-89. doi: 10.1016/j.bbamcr.2010.12.021. Epub 2011 Jan 4.

Supplemental Content

Loading ...
Support Center